Analytical Data
-
Gene name
PCSK6
- Application
-
Alternative Names
PACE4; SPC4; Paired Basic Amino Acid Cleaving System 4; Subtilisin-Like Proprotein Convertase 4; Subtilisin/Kexin-Like Protease PACE4
-
Species
Human
-
Source
E. coli
-
Tag
Two N- s, His- & SUMO-
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P29122
-
Expression Region
Met168~Val487
-
Molecular Weight
55kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PCSK6, or proprotein convertase subtilisin/kexin type 6, is a member of the proprotein convertase family, which plays a crucial role in the post-translational processing of various precursor proteins, influencing a range of biological processes, including metabolism, cell signaling, and development. Recent studies have highlighted PCSK6's involvement in several pathological conditions, including obesity, diabetes, and cardiovascular diseases, making it a potential therapeutic target. Additionally, PCSK6 is known to activate other convertases and neuropeptides by cleaving inactive precursor forms, thereby regulating their biological activity. The research on recombinant PCSK6 protein focuses on its enzymatic activity, structure-function relationships, and interaction with specific substrates, aiming to elucidate its role in disease mechanisms. Producing recombinant PCSK6 allows for detailed studies on its properties and potential inhibitor development, thereby paving the way for novel therapies aimed at modulating its activity in disease contexts. As the understanding of PCSK6 expands, it not only contributes to basic scientific knowledge but also holds promise for innovative clinical applications in managing diseases linked to its dysregulation.
